Prescription medicine
Eflapegrastim Brand names: Rolvedon
Eflapegrastim (Rolvedon) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the eflapegrastim FDA label on DailyMed (effective February 18, 2026); every eflapegrastim label on DailyMed.
Highlights of the record
FDA label of February 18, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageRolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
Forms and strengths
- 13.2 mg/.6ml
Injection (solution).
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 2 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 29 through July 30, 2026
What is eflapegrastim used for?
From the label: indications and usageRolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. Limitations of Use Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. […]
FDA pharmacologic class: Leukocyte Growth Factor.
Source: FDA drug label (Rolvedon), Spectrum Pharmaceuticals, Inc., effective February 18, 2026 (SPL set 6e436115-62e7-4729-aeb0-ff78ea685206), via openFDA; the full label on DailyMed
Is there a generic for eflapegrastim (Rolvedon)?
No generic eflapegrastim is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the eflapegrastim label say about other medicines?
The eflapegrastim label names 2 other medicines in its interaction, contraindication or warning sections. The labels of 1 other medicine name eflapegrastim. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Filgrastim | contraindications | CONTRAINDICATIONS Rolvedon is contraindicated in patients with a history of serious allergic reactions to eflapegrastim, pegfilgrastim, or filgrastim products. |
| Pegfilgrastim | contraindications | CONTRAINDICATIONS Rolvedon is contraindicated in patients with a history of serious allergic reactions to eflapegrastim, pegfilgrastim, or filgrastim products. |
Other labels that name eflapegrastim
Source: FDA drug label (Rolvedon), Spectrum Pharmaceuticals, Inc., effective February 18, 2026 (SPL set 6e436115-62e7-4729-aeb0-ff78ea685206), via openFDA; the full label on DailyMed
What do FAERS reports show for eflapegrastim?
The FDA Adverse Event Reporting System holds 29 reports that list eflapegrastim among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 4 are coded as a death and 10 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other leukocyte growth factors
- the pharmacologic class, with prices and generics
- Eflapegrastim side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other